טוען...
Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)
BACKGROUND: Brodalumab is efficacious for the treatment of moderate‐to‐severe plaque psoriasis through 52 weeks. OBJECTIVES: To evaluate the efficacy and safety of brodalumab through 120 weeks, including following withdrawal and retreatment. METHODS: At baseline, patients were randomized to brodalum...
שמור ב:
| הוצא לאור ב: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7754427/ https://ncbi.nlm.nih.gov/pubmed/32286683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.19132 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|